KDTA0B

KDTA0B is an investigational small molecule therapeutic being developed by KinDex Pharmaceuticals. It belongs to a class of compounds that target Type 2 Taste Receptors (TAS2Rs), which are G protein-coupled receptors (GPCRs) expressed both in the oral cavity and in various extra-oral tissues, including the airways, gastrointestinal tract, and immune cells. KDTA0B is specifically being explored for its potential in treating respiratory, metabolic, and inflammatory diseases. In the respiratory system, TAS2R agonists are known to promote bronchodilation by increasing intracellular calcium in smooth muscle cells through a mechanism distinct from beta-2 adrenergic receptors. In metabolic and inflammatory contexts, TAS2R modulation can influence the release of metabolic hormones and the production of pro-inflammatory cytokines.